Text Size

Pain Perception in Alzheimer's Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00192816
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The purpose of this study is to determine response to pain in Alzheimer's disease.We plan to study the effect of diffuse noxious inhibitory controls(counterirritation phenomenon)and the autonomic nervous system reaction(reflected by the heart rate) in Alzheimer's disease. The study's hypothesis is that pain perception and autonomic nervous system reaction are altered in Alzheimer's disease.


Condition Intervention
Dementia Alzheimer Type
 Behavioral: reaction to pain

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Pain Perception in Alzheimer's Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 60
Study Start Date: June 2005
  Eligibility

Ages Eligible for Study:   55 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

- Clinical diagnosis of Alzheimer's disease Must be able to understand a simple pain scale

Exclusion Criteria:

Neuropathy Psychotropic drugs use -

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00192816

Contacts
Contact: Maria Nassar, Doctor 0502061707 mashers@netvision.net.il

Locations
Israel
Neurocognitive unit,Neurophysiology laborator Rambam Health Care Campus Recruiting
Haifa, Israel, 31096
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Study Director: Judith Aharon-Peretz Rambam Health Care Campus
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00192816     History of Changes
Other Study ID Numbers: 2038CTIL
Study First Received: September 13, 2005
Last Updated: September 13, 2005
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 16, 2013